Statin treatment of children with familial hypercholesterolemia - Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?

Atherosclerosis

Volumn 226, Issue 2, 2013, Pages 315-320

  Vuorio, Alpo ^a,b   Docherty, Kieran F ^c   Humphries, Steve E ^d   Kuoppala, Jaana ^e   Kovanen, Petri T ^f  

^a Health Center Mehiläinen   (Finland)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c WESTERN INFIRMARY   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e Wihuri Research Institute ^*

^f WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Children; Coronary artery disease; Familial hypercholesterolemia; Low density cholesterol; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

BEHAVIOR THERAPY; CHOLESTEROL BLOOD LEVEL; CONSENSUS DEVELOPMENT; DRUG MEGADOSE; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATHEROSCLEROSIS; BRAIN; CAROTID INTIMA-MEDIA THICKNESS; CHILD; CHOLESTEROL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; RISK FACTORS; SOCIAL RESPONSIBILITY;

EID: 84872376838     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.032     Document Type: Review

References (62)

1. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic bases of inherited diseases 1995, McGraw-Hill Book Co, 1981-2030, New York, NY, n5r. 7th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Vuorio A., Kuoppala J., Kovanen P.T., et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev 2010 Jul 7, 7:CD006401.
3. Avis H.J., Hutten B.A., Gagné C., et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010, 55:1121-1126.
4. Rodenburg J., Vissers M.N., Wiegman A., et al. Statin treatment in children with familial hypercholesterolemia; the younger, the better. Circulation 2007, 116:664-668.
5. Belay B., Racine A.D., Belamarich P.F. Underpresentation of non-white children in trials of statins in children with heterozygous familial hypercholesterolemia. Ethn Dis 2009, 19:166-171.
6. Goldberg A.C., Robinson J.G., Cromwell W.C., Ross J.L., Ziajka P.E. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipidol 2011, 5(3 Suppl.):S46-S51.
7. National Institute of Clinical Excellence Identification and management of familial hypercholesterolaemia - clinical guideline CG71 August 2008, [visited 01.06.12]. http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf.
8. Risk estimation and the prevention of cardiovascular disease February 2007, Scottish Intercollegiate Guidelines Network, Scottish Intercollegiate Guidelines Network 28 Thistle Street, Edinburgh EH2 1EN, [visited 01.06.12]. http://www.sign.ac.uk/pdf/sign97.pdf.
9. Goldberg A.C., Hopkins P.N., Toth P.P., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. J Clin Lipidol 2011, 5(3 Suppl.):S1-S8.
10. Daniels S.R., Greer F.R. Lipid screening and cardiovascular health in children. Pediatrics 2008, 122:198-208.
11. Avis H.J., Vissers M.N., Stein E.A., et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007, 27:1803-1810.
12. Sullivan D.R., Hamilton-Craig I., van Bockxmeer F., et al. INTERIM guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung Circ 2012, 21:159-162.
13. Descamps O.S., Tenoutassa S., Stephenne X., et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 2011, 218:272-280.
14. McCrindle B.W., Urbina E.M., Dennison B.A., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension and Obesity Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007, 115:1948-1967.
15. Wertz D.C., Fletcher J.C., Berg K. Review of ethical issues in medical genetics 2003, World Health Organization, WHO/HGN/ETH/00.4, [visited 01.06.12]. http://www.who.int/genomics/publications/en/ethical_issuesin_medgenetics%20report.pdf.
16. Lorenz M.W., Schaefer C., Steinmetz H., Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). Eur Heart J 2010, 31:2041-2048.
17. Amato M., Montorsi P., Ravani A., et al. Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. Eur Heart J 2007, 28:2094-2101.
18. Wiegman A., de Groot E., Hutten B.A., et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004, 363:369-370.
19. Wiegman A., Hutten B.A., de Groot, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. J Am Med Assoc 2004, 292:331-337.
20. Masoura C., Pitsavos C., Aznaouridis K., Skoumas I., Vlachopoulos C., Stefanadis C. Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysis. Atherosclerosis 2011, 214:129-138.
21. Simon Broome Steering Committee Steering committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999, 142:105-112.
22. Neil A., Cooper J., Betteridge J., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29:2625-2633.
23. Vermissen J., Oosterveer D.M., Yazdanpanah M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br Med J 2008, 337:a2423.
24. Valenza M., Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. Prog Neurobiol 2006, 80:165-176.
25. Dietschy J.M., Turley S.D. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004, 45:1375-1397.
26. Porter F.D. Malformation syndromes due to inborn errors of cholesterol synthesis. J Clin Invest 2002, 110:715-724.
27. Miron V.E., Zehntner S.P., Kuhlman T., et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009, 174:1880-1890.
28. Dietschy J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 2009, 390:287-293.
29. de Ferranti S., Ludwig D.S. Storm over statins - the controversy surrounding pharmacologic treatment of children. New Engl J Med 2008, 359:1309-1312.
30. Braamskamp M.J.A.M., Wijburg F.A., Wiegman A. Drug therapy of hypercholesterolaemia in children and adolescents. Drugs 2012, 72:759-772.
31. Czoli C., Da Silva M., Shauk R.Z. Accountability and pediatric physician-researchers: are theoretical models compatible with Canadian lived experience?. Philos Ethics Humanit Med 2011, 6:15-23.
32. Avis H.J., Kusters M., Vissers M.N., et al. Follow-up of children diagnosed with familial hypercholesterolemia in National Genetic Screening Program. J Pediatr 2012 Jan 25, [Epub ahead of print].
33. Bogsryd M.P. 10 year follow-up of children with familial hypercholesterolemia following participation in the first statin trials May 25-28, 2012, Abstract in 80th European Atherosclerosis Society Congress, Milan, Italy.
34. Benn M., Watts G.F., Tybjaerg-Hansen A., Nordestgaard B.G. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrin Metab 2012, 10.1210/jc.2012-1563.
35. Hoeg J.M., Feuerstein I.M., Tucker E.E. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994, 14:1066-1074.
36. Defesche J.C., Lansberg P.J., Kastelein J.J.P. National screening and registration program for persons with familial hypercholesterolemia (FH). Atherosclerosis 1995, 64(Suppl.):S77.
37. Huijgen R., Hutten B.A., Kindt I., Vissers M.N., Kastelein J.J. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012, 5:354-359.
38. Starr B., Hadfield S.G., Hutten B.A., et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin Chem Lab Med 2008, 46:791-803.
39. Varni J.W., Limbers C.A., Burwinkle T.M. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the Peds QLTM 4.0 Generic Core Scales. J Health Qual Life Outcome 2007, 5:5-43.
40. Senior V., Marteau T.M., Peters T.J. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents responses to neonatal screening for familial hypercholesterolemia. Soc Sci Med 1999, 48:1857-1860.
41. Godard B., ten Kate L., Evers-Kiebooms G., Aymé S. Population genetic screening programmes: principles, techniques, practises, and policies. Eur J Hum Genet 2003, 11(Suppl. 2):S49-S87.
42. Leren T.P. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004, 66:483-487.
43. Tonstad S., Novik T.S., Vandvik I.H. Psychosocial function during treatment for familial hypercholesterolemia. Pediatrics 1996, 98:249-255.
44. de Jongh S., Kerckhoffs M.C., Grootenhuis M.A., Bakker H.D., Heymans H.S., Last B.F. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr 2003, 92:1096-1101.
45. Claassen L., Henneman L., Kindt I., Marteau T.H., Timmermans D.R. Perceived risk and representations of cardiovascular disease and preventive behaviour in people diagnosed with familial hypercholesterolemia: a cross-sectional questionnaire study. J Health Psychol 2010, 15:33-43.
46. Weiner K. Exploring genetic responsibility for the self, family and kin in the case of hereditary cholesterol. Soc Sci Med 2011, 72:1760-1767.
47. Chatzizisis Y.S., Koskinas K.C., Misirli G., Vaklavas C., Hatzitolios A., Giannoglou G.D. Risk factors and drug interactions predisposing to statin-induced myopathy. Drug Saf 2010, 33:171-187.
48. Koeijvoets K.C., Rodenburg J., Hutten B.A., Wiegman A., Kastelein J.J., Sijbrands E.J. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trials. Circulation 2005, 112:3168-3173.
49. Urbina E.M., Williams R.V., Alpert B.S., et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement form the American Heart Association. Hypertension 2009, 54:919-950.
50. Balagopal P., de Ferranti S.D., Cook S., et al. Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth. A scientific statement from the American Heart Association. Circulation 2011, 123:2749-2769.
51. O'Gorman C.S.M. Commentary on " statins for children with familial hypercholesterolemia" Evid Base Child Health 2011, 6:1132-1133.
52. Guardamagna O., Restagno G., Rolfo E., et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009, 155:199-204.
53. Schechter M.S., Margolis P. Improving subspecialty health care: lessons from cystic fibrosis. J Pediatr 2005, 147:295-301.
54. Schechter M.S., Gutierrez H.H. Improving the quality of care for patients with cystic fibrosis. Curr Opin Pediatr 2010, 22:296-301.
55. Guardamagna O., Abello F.A., Anfossi G., Pirro M. Lipoprotein(a) and family history of cardiovascular disease in children with familial dyslipidemias. J Ped 2011, 159:314-319.
56. Nenseter M.S., Lindvig H.W., Ueland T., et al. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 2011, 216:426-432.
57. Orsó E., Ahrens N., Kilalić D., Schmitz G. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors. Atherosclerosis 2009, 10(Suppl.):74-78.
58. Carreau V., Girardet J.-P., Bruckert E. Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia. Pediatr Drugs 2011, 13:267-275.
59. Cariou B., Le May C., Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011, 216:258-265.
60. Visser M.E., Witztum J.L., Stroes E.S., Kastelein J.J. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012, 33:1451-1458.
61. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
62. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011, 305:2556-2564.